Rachid Baz, MD
Novel combination regimens that include daratumumab (Darzalex), the anti-CD38 monoclonal antibody, are on the rise and producing significantly improved outcomes for patients with multiple myeloma, although therapeutic sequencing challenge exists.
State of the Science Summit™ on Hematologic Malignancies. In an interview, he spoke to the change in risk factors for select treatments, the impact of daratumumab, and the current sequencing questions among the field.
OncLive: What was the basis of your discussion on multiple myeloma?
: Over the past few years, we have had a lot of new treatment options for patients with myeloma—certainly, those with newly diagnosed disease. I divided the talk into approaches for patients who are elderly or frail versus patients who are younger or fit. Traditionally, we separated patients based on their eligibility for stem cell transplant, although, we now rely more on frailty than age.
How do you treat these 2 patient groups differently?
Historically, we used to avoid alkylating agents, like melphalan, for patients who are eligible for transplant because of concern over difficulty mobilizing stem cells. You consider the elderly patients’ therapy to be traditionally melphalan-based. Now there is considerable evidence that melphalan is not a required treatment for the elderly and frail patients either.
... to read the full story